Weight-loss drug lawsuit raises questions about possible blindness risk
A new lawsuit is raising concerns about a possible link between popular GLP-1 weight-loss drugs and blindness. Medications like Ozempic and Wegovy have surged in popularity, but the legal action alleges some users suffered serious vision problems.
Read more: https://www.boston25news.com/news/local/lawsuit-claims-link-between-glp-1-weight-loss-drugs-blindness/QGSS4LEZNNHTXCKJQ7Y46JDVNI/
Follow Boston 25 News on:
YouTube: https://www.youtube.com/@Boston25News
Facebook -- https://www.facebook.com/Boston25News
X -- https://x.com/boston25
Instagram -- https://www.instagram.com/boston25/
TikTok -- https://www.tiktok.com/@b25news?lang=en
Download the Boston 25 News app: https://www.boston25news.com/mobile-apps/
Video Summary
AI GeneratedDozens of patients, including a Massachusetts man, are filing a multi-district lawsuit against GLP-1 drug makers like Novo Nordisk and Eli Lilly. Plaintiffs claim these weight-loss and diabetes medications caused Non-Arteritic Ischemic Optic Neuropathy (NAION), leading to sudden, permanent vision loss, and allege that manufacturers failed to warn users despite known risks.